AJANTPHARM Ajanta Pharma Q1 FY26 results (Apr–Jun 2025) and concall
Ajanta Pharma reported a strong start to FY26 with 14% revenue growth, driven by robust performance in India and US Generics. Gross margins expanded, and financial ratios improved. However, profitability was impacted by higher operating expenses and a significant mark-to-market FOREX loss, leading to a modest 4% PAT growth. The Africa branded business saw a slight degrowth, while the cardiology segment faced increased competition.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 1,187 | 1,146 | 1,170 | 1,303 |
| EBITDA | 311 | 321 | 297 | 351 |
| Net profit | 216 | 233 | 225 | 255 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
